Table 1 Demographic and clinical characteristics of 460 patients with hepatocellular carcinoma (HCC)

Sex

 Men

132 (83.0)

235 (78.1)

 Women

27 (17.0)

66 (21.9)

Age (years)^a

54.0 ± 11.0

54.2 ± 11.0

 ≤65

138 (86.8)

255 (84.7)

 >65

21 (13.2)

46 (15.3)

Heredity

 Yes

6 (3.8)

16 (5.3)

 No

153 (96.2)

285 (94.7)

Etiology

 Cryptogenic

21 (13.2)

38 (12.6)

 HBV infection

128 (80.5)

250 (83.0)

 HCV infection

8 (5.0)

11 (3.7)

 Schistosomiasis

2 (1.3)

2 (0.7)

Tumor size (cm)^a

1.7 ± 0.3

1.7 ± 0.3

Tumor location

 Favorable

121 (76.1)

210 (69.8)

 Unfavorable

38 (23.9)

91 (30.2)

Child–Pugh class

 Class A

140 (88.1)

278 (92.4)

 Class B

19 (11.9)

23 (7.6)

HBV-DNA^b

 Positive

70 (44.0)

107 (35.5)

 Negative

58 (36.5)

143 (47.5)

 Absent

31 (19.5)

51 (16.9)

ALT (U/L)^a

38.28 ± 23.22

38.37 ± 26.80

 <40

113 (71.1)

237 (78.7)

 40–80

36 (22.6)

57 (18.9)

 >80

10 (6.3)

7 (2.4)

TBIL (μmol/L)^a

17.53 ± 8.33

17.51 ± 8.53

 ≤20

108 (67.9)

217 (72.1)

 >20

51 (32.1)

84 (27.9)

DBIL (μmol/L)^a

6.80 ± 3.91

7.33 ± 4.83

 ≤7

104 (65.4)

177 (58.8)

 >7

55 (34.6)

124 (41.2)

ALB (g/L)^a

40.60 ± 5.49

41.21 ± 5.31

 <35

25 (15.7)

38 (12.6)

 ≥35

134 (84.3)

263 (87.4)

GGT (U/L)^a

85.79 ± 83.51

77.98 ± 113.45

 <50

89 (56.0)

187 (62.1)

 50–100

38 (23.9)

75 (24.9)

 >100

32 (20.1)

39 (13.0)

PLT (×10⁹/L)^a

120.37 ± 55.13

122.60 ± 60.00

 <100

67 (42.1)

122 (40.5)

 ≥100

92 (57.9)

179 (59.5)

PT (s)^a

12.9 ± 1.3

12.9 ± 1.3

 ≤13

101 (63.5)

185 (61.5)

 >13

58 (36.5)

116 (38.5)

AFP level (μg/L)

 <20

69 (43.4)

156 (51.8)

 20–200

44 (27.7)

80 (26.6)

 >200

46 (28.9)

65 (21.6)

CA19-9 (kU/L)

 ≤39

107 (67.3)

228 (75.7)

 >39

52 (32.7)

73 (24.3)

Hospital stay (days)^a

3.4 ± 1.7

3.4 ± 2.3